A detailed history of Geode Capital Management, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,154,035 shares of MYGN stock, worth $29.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,154,035
Previous 2,132,815 0.99%
Holding current value
$29.4 Million
Previous $52.2 Million 13.01%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.97 - $28.6 $508,643 - $606,892
21,220 Added 0.99%
2,154,035 $59 Million
Q2 2024

Aug 09, 2024

BUY
$17.98 - $25.47 $2.09 Million - $2.97 Million
116,443 Added 5.77%
2,132,815 $52.2 Million
Q1 2024

May 13, 2024

BUY
$17.59 - $23.59 $2.54 Million - $3.41 Million
144,515 Added 7.72%
2,016,372 $43 Million
Q4 2023

Feb 13, 2024

BUY
$13.91 - $21.32 $2.02 Million - $3.09 Million
144,973 Added 8.4%
1,871,857 $35.8 Million
Q3 2023

Nov 13, 2023

BUY
$15.99 - $23.22 $991,971 - $1.44 Million
62,037 Added 3.73%
1,726,884 $27.7 Million
Q2 2023

Aug 11, 2023

BUY
$17.56 - $23.76 $1.07 Million - $1.44 Million
60,740 Added 3.79%
1,664,847 $38.6 Million
Q1 2023

May 15, 2023

BUY
$15.26 - $23.75 $1.2 Million - $1.86 Million
78,333 Added 5.13%
1,604,107 $37.3 Million
Q4 2022

Feb 13, 2023

BUY
$14.51 - $20.99 $798,108 - $1.15 Million
55,004 Added 3.74%
1,525,774 $22.1 Million
Q3 2022

Nov 14, 2022

BUY
$18.21 - $27.88 $463,954 - $710,326
25,478 Added 1.76%
1,470,770 $28.1 Million
Q2 2022

Aug 12, 2022

SELL
$16.45 - $25.88 $43,839 - $68,970
-2,665 Reduced 0.18%
1,445,292 $26.3 Million
Q1 2022

May 13, 2022

BUY
$22.67 - $28.01 $427,986 - $528,800
18,879 Added 1.32%
1,447,957 $36.5 Million
Q4 2021

Feb 11, 2022

BUY
$24.13 - $32.63 $1.19 Million - $1.61 Million
49,362 Added 3.58%
1,429,078 $39.4 Million
Q3 2021

Nov 12, 2021

BUY
$29.97 - $36.66 $478,051 - $584,763
15,951 Added 1.17%
1,379,716 $44.6 Million
Q2 2021

Aug 13, 2021

BUY
$25.39 - $32.61 $2.54 Million - $3.26 Million
100,088 Added 7.92%
1,363,765 $41.7 Million
Q1 2021

May 12, 2021

BUY
$19.92 - $31.6 $2.38 Million - $3.78 Million
119,711 Added 10.46%
1,263,677 $38.5 Million
Q4 2020

Feb 12, 2021

BUY
$12.16 - $19.77 $256,478 - $416,988
21,092 Added 1.88%
1,143,966 $22.6 Million
Q3 2020

Nov 13, 2020

SELL
$11.25 - $14.75 $256,803 - $336,698
-22,827 Reduced 1.99%
1,122,874 $14.6 Million
Q2 2020

Aug 13, 2020

BUY
$10.69 - $16.49 $439,091 - $677,326
41,075 Added 3.72%
1,145,701 $13 Million
Q1 2020

May 14, 2020

BUY
$9.78 - $29.53 $499,493 - $1.51 Million
51,073 Added 4.85%
1,104,626 $15.8 Million
Q4 2019

Feb 13, 2020

BUY
$20.93 - $35.1 $911,941 - $1.53 Million
43,571 Added 4.31%
1,053,553 $28.7 Million
Q3 2019

Nov 12, 2019

BUY
$22.08 - $47.08 $254,781 - $543,256
11,539 Added 1.16%
1,009,982 $28.9 Million
Q2 2019

Aug 14, 2019

BUY
$22.67 - $35.0 $1.62 Million - $2.51 Million
71,670 Added 7.73%
998,443 $27.7 Million
Q1 2019

May 14, 2019

BUY
$26.93 - $34.7 $1.27 Million - $1.64 Million
47,324 Added 5.38%
926,773 $30.8 Million
Q4 2018

Feb 13, 2019

BUY
$27.23 - $45.56 $2.82 Million - $4.72 Million
103,528 Added 13.34%
879,449 $25.6 Million
Q3 2018

Nov 13, 2018

BUY
$37.57 - $50.34 $1.61 Million - $2.16 Million
42,900 Added 5.85%
775,921 $35.7 Million
Q2 2018

Aug 14, 2018

BUY
$27.75 - $40.17 $1.58 Million - $2.28 Million
56,762 Added 8.39%
733,021 $27.4 Million
Q1 2018

May 15, 2018

BUY
$28.83 - $41.01 $1.71 Million - $2.44 Million
59,463 Added 9.64%
676,259 $20 Million
Q4 2017

Feb 13, 2018

SELL
$28.45 - $37.14 $1.21 Million - $1.58 Million
-42,631 Reduced 6.46%
616,796 $21.2 Million
Q3 2017

Nov 14, 2017

BUY
$24.01 - $36.2 $133,303 - $200,982
5,552 Added 0.85%
659,427 $23.9 Million
Q2 2017

Aug 14, 2017

BUY
N/A
653,875
653,875 $16.9 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.1B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.